Reaction to news that BioNTech plans to ship mobile vaccine factory kits to Africa

Publié: 16th février 2022

Responding to the announcement that BioNTech plans to ship mobile vaccine factory containers to Africa, which could start producing vaccines in the second half of 2023, Oxfam’s Health Policy Manager, Anna Marriott, said: 

“Efforts to boost vaccine manufacturing in Africa are welcome but this is a long-term project and should not distract from the failure of rich country governments and companies, including Germany and BioNTech, to tackle today’s shameful vaccine inequality responsible for millions of needless deaths in poorer countries from this pandemic.

“It is unacceptable that BioNTech, along with other pharma giants, is ignoring the World Health Organisation’s mRNA Hub in Africa which is ready to produce vaccines and expand manufacturing in favour of a BioNTech controlled vaccine container module that won’t be producing vaccines for well over a year. 

“To date, Germany has exported just one per cent of its vaccines to the African continent. If Germany is serious about tackling vaccine inequality it must reverse its refusal to support the waiving of intellectual property rules for these life-saving pandemic tools and insist BioNTech transfer their technology now to the World Health Organisation so that existing manufacturers across Africa, Latin America and Asia can make them.

“Serious questions must also be raised about BioNTech’s objectives with this initiative. Last week, it was revealed that a consultancy on BioNTech’s payroll, the kENUP Foundation, is trying to undermine the work of a World Health Organisation and South African-led project to make mRNA COVID vaccines as a global public good and free of big pharma’s control.”

Notes aux rédactions

Vaccine equity: Oxfam, as part of the People’s Vaccine Alliance, advocates for the fair and equal distribution of vaccines around the world. The EU should support the proposal at the WTO, which is backed by 100 countries, to temporarily suspend intellectual property rules for COVID-19 vaccines, tests, and treatments. 


Sarah Dransfield in the UK | | +44 (0)7884 114825
Jade Tenwick in Brussels, Belgium | | +32 (0) 473 56 22 60

For updates, please follow @NewsFromOxfam and @Oxfam 

Please support Oxfam's Coronavirus Response Appeal.

Tagged with